Legal Battle Over GAO Report
The DEA claims its proposal to reclassify marijuana is unshaken by a GAO report that exposed critical procedural gaps.
A federal judge rejected opponents’ request to reopen the hearing for new testimony, yet allowed the GAO report into the record and ordered parties to submit briefs on how much weight the document should carry.
DEA’s Thursday brief asks Judge Derek Julius to give the GAO report “no weight,” arguing it contains no probative evidence on abuse potential, accepted medical use, or dependence risk—key factors for scheduling decisions.
The GAO report found that neither the DEA nor the FDA has formal policies or procedures for evaluating or scheduling controlled substances, raising doubts about the scientific rigor of the rescheduling process.
DEA contends the report’s abuse analysis relies on factors publicly available for over two years, and that any disagreement with the methodology does not invalidate the underlying data.
Opponents, including the National Drug & Alcohol Screening Association, DUID Victim Voices, and Kenneth Finn, argue the GAO document “deserves decisive weight” because it shows the government lacks a documented, reviewable basis for its recommendations and cannot meet its burden of proof.
Their joint brief states the tribunal should reject the proposed rescheduling to Schedule III on the existing record, citing the absence of written procedures that guard against outside influence.
Anti‑rescheduling groups note the process began with direct presidential direction and massive industry financing, with Trulieve actively lobbying the Trump inauguration committee, underscoring unprecedented financial stakes.
They claim an agency relying on “unwritten professional judgment” cannot verify that evidence—not lobbying or political pressure—drove the proposal, and therefore the government fails to satisfy its evidentiary burden.
Smart Approaches to Marijuana and the states of Idaho, Indiana, and Nebraska echo these concerns, asserting that without standardized policies the FDA could arbitrarily manipulate abuse comparators to reach pre‑ordained conclusions.
The groups demand a new HHS evaluation under a written FDA policy that addresses relative‑abuse comparisons, medical‑use frameworks, product variability, dosing, public‑health risks, and diversion before any rescheduling decision.
DOJ’s Office of Legal Counsel previously opined that the five‑part test was “impermissibly narrow,” while the two‑part review it endorses is sufficient to establish currently accepted medical use.
The Tennessee Bureau of Investigation submits that GAO findings are competent, relevant evidence showing the Attorney General’s notice of proposed rulemaking departed from required procedures.
No reply briefs are due, but parties may file them by next Thursday, November 5.
Judge Julius said requests for additional testimony were largely immaterial, though he permitted further briefing on the GAO report.
DEA maintains the hearing record already includes the GAO document and opposes any additional briefings, labeling the request to reopen the hearing as an “obvious fishing expedition.”
Attorney General Todd Blanche’s April order reclassified state‑licensed medical cannabis and FDA‑approved products from Schedule I to Schedule III, and a June order authorized a comprehensive hearing on rescheduling.
DEA attorney James Schwartz warned that all controlled substances are inherently dangerous and must be weighed against their accepted medical benefits.
The agency argues that over 30,000 practitioners treat more than six million patients across 43 jurisdictions, demonstrating accepted safety under medical supervision and making Schedule I inappropriate.
DEA also asserts that marijuana’s abuse and dependency profiles align with Schedule III rather than Schedule I or II, citing low rates of serious community harm.
It urges the judge to expedite a recommendation to transfer marijuana from Schedule I to Schedule III, citing robust medical evidence and professional endorsement.
Meanwhile, opponents highlight alleged health harms and criticize the new two‑part analysis method for deviating from established standards, arguing the process remains arbitrary and capricious.
